Current Issues in Liver Transplantation.

A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06

Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11

Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol (2013) 3.36

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology (2015) 3.27

An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04

Addressing geographic disparities in liver transplantation through redistricting. Am J Transplant (2013) 2.46

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology (2014) 2.27

Increasing the Number of Organ Transplants in the United States by Optimizing Donor Authorization Rates. Am J Transplant (2015) 2.13

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07

Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant (2010) 1.93

Redrawing organ distribution boundaries: results of a computer-simulated analysis for liver transplantation. Liver Transpl (2002) 1.51

Early changes in liver distribution following implementation of Share 35. Am J Transplant (2015) 1.36

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21

MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA (2004) 1.17

Robust Models Support Redistricting Liver Allocation to Reduce Geographic Disparity. Transplantation (2015) 1.12

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol (2014) 1.10

De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant (2013) 1.07

The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant (2014) 0.96

Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant (2012) 0.95

Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88

Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 0.85

Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl (2014) 0.83

Financial Impact of Liver Sharing and Organ Procurement Organizations' Experience With Share 35: Implications for National Broader Sharing. Am J Transplant (2015) 0.82

Liver sharing and organ procurement organization performance under redistricted allocation. Liver Transpl (2015) 0.78

Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. Am J Transplant (2015) 0.78